- Home
- BCDA vs SBFM Comparison
BCDA vs SBFM Comparison
Compare BCDA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SBFM
- Stock Information
- Founded
- BCDA N/A
- SBFM 2006
- Country
- BCDA United States
- SBFM United States
- Employees
- BCDA N/A
- SBFM N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- SBFM Health Care
- Exchange
- BCDA Nasdaq
- SBFM Nasdaq
- Market Cap
- BCDA 7.9M
- SBFM 3.7M
- IPO Year
- BCDA N/A
- SBFM N/A
- Fundamental
- Price
- BCDA $2.68
- SBFM $3.06
- Analyst Decision
- BCDA Strong Buy
- SBFM
- Analyst Count
- BCDA 1
- SBFM 0
- Target Price
- BCDA $25.00
- SBFM N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- SBFM 121.6K
- Earning Date
- BCDA 11-06-2024
- SBFM 11-11-2024
- Dividend Yield
- BCDA N/A
- SBFM N/A
- EPS Growth
- BCDA N/A
- SBFM N/A
- EPS
- BCDA N/A
- SBFM N/A
- Revenue
- BCDA $428,000.00
- SBFM $30,481,982.00
- Revenue This Year
- BCDA $6.92
- SBFM $86.70
- Revenue Next Year
- BCDA N/A
- SBFM $126.76
- P/E Ratio
- BCDA N/A
- SBFM N/A
- Revenue Growth
- BCDA 0.71
- SBFM 109.82
- 52 Week Low
- BCDA $1.96
- SBFM $2.42
- 52 Week High
- BCDA $23.25
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- SBFM 49.32
- Support Level
- BCDA $2.39
- SBFM $2.85
- Resistance Level
- BCDA $2.90
- SBFM $3.05
- Average True Range (ATR)
- BCDA 0.18
- SBFM 0.15
- MACD
- BCDA -0.00
- SBFM 0.02
- Stochastic Oscillator
- BCDA 53.70
- SBFM 63.89
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.